上方“瞪羚社”即刻关注并加入社群聚焦高成长公司,100000+投资菁英共同关注胰淀素(Amylin)再度掀起了减重领域的热议,Metsera公布首创每月一次淀粉样蛋白候选药物MET-233i的积极1期临床数据。目前呈现的是冰火两重天的趋势。一方面,诺和诺德关于胰淀素的复方制剂cagrisema三期临床并不达预期,股价再次迎来了华尔街的看空;另一方面,前面数月罗氏license in了胰淀素相关的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.